Polycystic Ovary Syndrome
ELAGOLIX: AN INVESTIGATIONAL TREATMENT FOR POLYCYSTIC OVARY SYNDROME
Gonadotropin-releasing hormone, or GnRH, is a peptide that stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function.
Elagolix is an orally active, non-peptide GnRH antagonist, being investigated for the treatment of PCOS. Polycystic Ovary Syndrome (PCOS) is one of the most common hormonal disorders among women of reproductive age, affecting approximately 3.5 million women in the United States. PCOS occurs when the ovaries or adrenal glands produce more male hormones (androgens) than normal. Women with PCOS experience irregular menstrual periods, infertility, pelvic pain, weight gain, acne, and excess hair growth on the face, chest, stomach and thighs. There is no cure for PCOS, and treatment options are limited. If left untreated, PCOS can lead to certain cancers, diabetes, and/or coronary artery disease.
Pursuant to the collaboration between Neurocrine Biosciences and AbbVie, AbbVie intends to initiate a study of elagolix in women with PCOS. The study is designed to evaluate whether there is a potential impact on disordered hormonal dynamics in women with PCOS. AbbVie is responsible for all development, marketing and commercialization costs of elagolix.